Treating or preventing ocular inflammation or systemic imflammatory disease

Abstract

A novel compound for controlling (treatment and prevention) of ocular inflammation or systemic inflammatory disease is disclosed. The compound, OB-186, is effective at both the early and late phases of inflammation. The compound is useful for the treatment or prevention of inflammation in both the anterior and posterior portions of the eye and systemic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, glyomerulonephritis, allergic inflammation and allergic encephalomyelitis.